OrthoPediatrics (NASDAQ:KIDS) Director Sells 18,000 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 18,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $24.28, for a total value of $437,040.00. Following the completion of the sale, the director owned 6,863,464 shares of the company’s stock, valued at $166,644,905.92. This represents a 0.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

OrthoPediatrics Stock Performance

Shares of NASDAQ:KIDS traded down $0.47 during trading on Wednesday, hitting $24.03. 169,608 shares of the stock were exchanged, compared to its average volume of 171,545. OrthoPediatrics Corp. has a 1-year low of $14.42 and a 1-year high of $26.74. The company has a market capitalization of $627.42 million, a price-to-earnings ratio of -14.30 and a beta of 0.98. The company’s fifty day simple moving average is $21.11 and its 200-day simple moving average is $18.53. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The business had revenue of $70.51 million during the quarter, compared to analyst estimates of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. Sell-side analysts expect that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

KIDS has been the subject of a number of recent research reports. Truist Financial set a $22.00 price objective on shares of OrthoPediatrics in a research note on Wednesday, August 5th. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Weiss Ratings raised shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. BTIG Research raised their price target on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $26.44.

Institutional Investors Weigh In On OrthoPediatrics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. grew its holdings in shares of OrthoPediatrics by 433.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after purchasing an additional 1,139 shares during the last quarter. Legal & General Group Plc acquired a new position in OrthoPediatrics in the second quarter valued at about $34,000. Northwestern Mutual Wealth Management Co. grew its stake in OrthoPediatrics by 5,226.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after buying an additional 2,561 shares during the last quarter. Caption Management LLC bought a new stake in OrthoPediatrics during the third quarter worth about $54,000. Finally, BNP Paribas Financial Markets raised its stake in shares of OrthoPediatrics by 60.2% in the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after acquiring an additional 1,235 shares during the last quarter. Institutional investors and hedge funds own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.